Pharmacokinetics and tolerability evaluation of human coagulation recombinant factor VIII (Greengenetm™) in hemophilia a patients

Abstract

Background: GreenGene™ (Green Cross Corp.) is a recombinant clotting factor vii which is used for hemophilia A. This study aimed to investigate the pharmacokinetics and safety profiles of 25 IU/kg and 50 IU/kg of GreenGene™ in Korean hemophilia A patients. Methods: A dose-block randomized, single-blind, active drug-controlled, single and multiple dose, parallel-group study was conducted with 16 hemophilia A patients (25 IU/kg: 50 IU/kg = 8:8). They received GreenGene™ or GreenMono™(active control) intravenously on day 1 and every other day from day 4 to 10. Fvii:C (Factor vii procoagulant activity) was measured to determine the pharmacokinetics (PK) at baseline and up to 48 hours for single and multiple administration. PK parameters were determined using noncompartmental methods. Results: The maximum concentration (Cmax) and the area under the concentration-time curve (AUC0-48) of the GreenGene™ 25 IU/kg (mean ± SD) were 59.00 ± 19.26 % and 774.40 ± 380.13 %·h respectively, while those of 50 IU/kg were 131.50 ± 39.81 % and 1462.44 ± 397.09 %·h after single administration. The Cmax and AUC0-48 in steady state of the GreenGene™ 25 IU/kg were 68.17 ± 22.75 % and 863.30 ± 334.40 %·h, while those of 50 IU/kg were 147.17 ± 18.47 % and 1820.08 ± 704.42 %·h. No serious adverse event was observed. Conclusion: The GreenGene™ to hemophilia A patients appeared to be well tolerated within range of 25-50 IU/kg. The PK parameters of factor vii showed dose-independent manner with 25 IU/kg and 50 IU/kg dose ranges.